TEVA, US8816242098

Teva stock at USD 41.62 with P/ E 65.3

Published on 10/09/2026 at 18:05 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Teva stock stood at USD 41.62 on October 9, 2026, up 6.0 percent. Its 52-week high is USD 42.02 and market value is USD 48.5 billion.

Key points in brief

Teva stock traded at USD 41.62 on October 9, 2026, with a plus 6.03 percent session move.
The stock was USD 0.40 below its USD 42.02 52-week high.
Teva had a USD 48.5 billion market capitalization and a P/E ratio of 65.31.
Third-quarter 2026 results are scheduled for November 3, 2026.

TEVA, US8816242098, Illustration mit AI erstellt.

At USD 41.62 on October 9, 2026, Teva Pharmaceutical Industries stock was trading 6.03 percent higher on the session, with the price USD 0.40 below its USD 42.02 52-week high. The move puts the stock close to its yearly peak while the valuation remains the key market measure.

Price nears the yearly high

The USD 41.62 price was recorded at 12:03 p.m. ET on the NYSE, where the session change was plus 6.03 percent. Trading volume reached 7,128,371 shares against an average volume of 5,300,579, giving the move a volume ratio of 1.34 times the average.

Teva's 52-week range was USD 18.83 to USD 42.02 on October 9, 2026. The latest price therefore stood 0.95 percent below the high, calculated from the USD 0.40 gap to USD 42.02.

Valuation remains the market test

Teva's market capitalization was USD 48.5 billion on October 9, 2026, while its price-to-earnings ratio was 65.31. That combination makes the next earnings release important for investors because the share price is already close to the upper end of its annual range.

Teva operates in healthcare and specialty and generic drug manufacturing. Its profile includes generic medicines, specialty therapies, biosimilars and active pharmaceutical ingredients, with central nervous system, respiratory and oncology products among its therapeutic areas.

Comparison with peers

Teva: plus 6.03 percent, P/E 65.31, market capitalization USD 48.5 billion.
Viatris (NYSE, USD): plus 0.54 percent, P/E minus 48.65, market capitalization USD 20.4 billion.
Bristol-Myers Squibb (NYSE, USD): minus 0.56 percent, P/E 13.06, market capitalization USD 121.0 billion.

November results set the next date

According to Globenewswire in the company release dated September 23, 2026, Teva will issue its third-quarter 2026 results on November 3, 2026, at 7:00 a.m. ET and host its conference call at 8:00 a.m. ET. The release identifies Teva as listed on the NYSE and TASE under the symbol TEVA.